• Home
  • PGRN Collaboration Grant



RFA Opens: Oct 01, 2021

RFA Closes: Dec 03, 2021

Project Period 12 months from funding date

Grant Award will be announced in February 2022

Grant Award: Up to $20,000


Collaboration Resource

Please fill out information about cohorts you have access to and would be willing to collaborate on for this or future projects. Responses to columns are optional, but please fill in as much information as you can because this will allow better understanding of the collaborative opportunities. You may fill in more than one line if you have more than one disease area that can be studied using a cohort.

Mission

The mission of the Pharmacogenomics Global Research Network (PGRN) Research Collaborative Grant is to foster collaboration among PGRN members to advance the science of pharmacogenomics as it relates to all aspects of precision medicine. Grants up to $20,000 will be awarded on a competitive basis to PGRN members who enter into collaborative arrangements, including with other academic researchers or industry partners. The program will consider submission of proposals from a wide range of approaches but is particularly interested in projects that pool existing data from several previously conducted analyses, for example projects that:

      Perform meta-analyses to generalize novel pharmacogenetic association(s) of key clinical relevance (a pharmacokinetic or treatment outcome).

      Model the effects of multiple variants/genes on a pharmacokinetic or treatment outcome in vitro.

      Pooled analyses to determine the effects of genetic variation in experimental models.

      Determine the effect of genetics-guided treatment on a pharmacokinetic or treatment outcome from an existing dataset.

      Validate a pharmacogenetic associations in an independent patient cohort with similar treatment and clinical endpoints.

      Mechanistically validate a pharmacogenetic association using experimental model systems or human samples (e.g., cellular models, animal studies or plasma markers).

Proposals that include international collaboration and participants from diverse and understudied populations will be prioritized. Proposals that require patient, data, or sample collection are acceptable, but will require compelling evidence of feasibility of completing collection within the grant time frame.

Proposals will be reviewed on the basis of scientific merit and significance, strength of the collaborative effort, qualifications of the investigator team and the potential for future funding. It is anticipated that one grant will be awarded this year. The funding can be used for a variety of purposes, but is expected to be used for effort for individuals to collect, clean, merge, and analyze the existing data. Funding for additional genotyping in pharmacogenetic validation studies, for example, is acceptable. The awardees will be required to present the results of their research at a future PGRN Research in Progress Symposium and/or PGRN Annual Meeting.

Eligibility

Applicants must be PGRN members and current with dues during the project period. Trainees are eligible with faculty sponsorship documented in a letter of support.

Proposal
No more than 4 pages...not including references but put in same .pdf

The following sections should be included in your proposal. Applicants have flexibility in the organization but all of the following sections are required.

  1. Aims (no more than 1 page)
  2. Background and Significance
  3. Collaborative team - including description of investigators and data use agreements
  4. Research strategy and approach (including statistical analysis). Studies focused on diverse and understudied populations are encouraged.
  5. Description of data sharing plan and agreements with milestones
  6. Timeline

Budget and justification (half page)

This grant will provide up to $20,000 in project costs. Provide a detailed budget and justification that will be considered in the review. Budgets should be realistic and any additional funds available to contribute to the project should be discussed. Indirect costs are not allowed. If institutions mandate indirect funding, please reach out to the grants administrator for further discussion (grants@pgrn.org).

Criteria for Review

Proposals will be reviewed by a Grant Review Committee composed of PGRN members with appropriate expertise. Scorable criteria include significance, study design and analysis, strength of collaborations, inclusion of diverse and understudied populations, feasibility of completion during funding period, and potential future funding. Each proposal will be reviewed by at least two reviewers and scores will be reviewed for prioritization for funding by the entire review panel. Reviewer comments will be shared with all applicants after the final funding decision. The final selection for funding will be made by the PGRN Executive Council.

HOW TO APPLY

Combine the Proposal, Budget and CV's of PI collaborators, references into a single .pdf

Send as an attachment to: Grants@pgrn.org

Deadline: Midnight (EST) on Dec 03, 2021

Characterization of Cohorts/Phenotypes Available for Collaborative Studies

Please fill out information about cohorts you have access to and would be willing to collaborate on for this or future projects. Responses to columns are optional, but please fill in as much information as you can because this will allow better understanding of the collaborative opportunities. You may fill in more than one line if you have more than one disease area that can be studied using a cohort.


Copyright © 2020 the Pharmacogenomics Global Research Network. All Rights Reserved.

PGRN is a 501(c)3 Non-Profit Association

Follow us on


Become a Member

PGRN logo
Membership dues are vital to continue the mission and work of the PGRN. Join your colleagues today and suport the work of PGRN. 
Powered by Wild Apricot Membership Software